Impact of prophylactic immediate posttransplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study.
作者： Hannah A. Valantine , Shao-Zhou Gao , Santosh G. Menon , Dale G. Renlund , Sharon A. Hunt
关键词: Placebo 、 Transplantation 、 Internal medicine 、 Human cytomegalovirus 、 Heart transplantation 、 Ganciclovir 、 Medicine 、 Surgery 、 Immunosuppression 、 Azathioprine 、 Placebo-controlled study
摘要: Background—Coronary artery disease occurs in an accelerated fashion the donor heart after transplantation (TxCAD), but cause is poorly understood. The risk of developing TxCAD increased by cytomegalovirus (CMV) infection and decreased use calcium blockers. Our group observed that prophylactic administration ganciclovir early inhibited CMV illness, we now propose to determine whether this therapy also prevents TxCAD. Methods Results—One hundred forty-nine consecutive patients (131 men 18 women aged 48±13 years) were randomized receive either or placebo during initial 28 days transplantation. Immunosuppression consisted muromonab-CD3 (OKT-3) prophylaxis maintenance with cyclosporine, prednisone, azathioprine. Mean follow-up time was 4.7±1.3 years. In a post hoc analysis trial designed assess efficacy for prevention disease, compared actuarial incidence TxCAD, ...
sci-hub.se 参考文章(20)
Shao-Zhou Gao, Edwin L. Alderman, John S. Schroeder, James F. Silverman, Sharon A. Hunt, Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. Journal of the American College of Cardiology. ,vol. 12, pp. 334- 340 ,(1988) , 10.1016/0735-1097(88)90402-0
Karl Lemström, Petri Koskinen, Leena Krogerus, Mat Daemen, Cathrien Bruggeman, Pekka Häyry, Cytomegalovirus Antigen Expression, Endothelial Cell Proliferation, and Intimal Thickening in Rat Cardiac Allografts After Cytomegalovirus Infection Circulation. ,vol. 92, pp. 2594- 2604 ,(1995) , 10.1161/01.CIR.92.9.2594
K B Lemström, J H Bruning, C A Bruggeman, P K Koskinen, P T Aho, S Yilmaz, I T Lautenschlager, P J Häyry, Cytomegalovirus infection-enhanced allograft arteriosclerosis is prevented by DHPG prophylaxis in the rat. Circulation. ,vol. 90, pp. 1969- 1978 ,(1994) , 10.1161/01.CIR.90.4.1969
J Thyberg, U Hedin, M Sjölund, L Palmberg, B A Bottger, Regulation of differentiated properties and proliferation of arterial smooth muscle cells. Arteriosclerosis, Thrombosis, and Vascular Biology. ,vol. 10, pp. 966- 990 ,(1990) , 10.1161/01.ATV.10.6.966
Mark T. Grattan, Cytomegalovirus Infection Is Associated With Cardiac Allograft Rejection and Atherosclerosis JAMA: The Journal of the American Medical Association. ,vol. 261, pp. 3561- 3566 ,(1989) , 10.1001/JAMA.1989.03420240075030
Ken McDonald, Thomas S. Rector, Elizabeth A. Braunlin, Spencer H. Kubo, Maria Teresa Olivari, Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. American Journal of Cardiology. ,vol. 64, pp. 359- 362 ,(1989) , 10.1016/0002-9149(89)90535-3
John A. Wagner, Heather Ross, Sharon Hunt, Patricia Gamberg, Hannah Valantine, Thomas C. Merigan, Edward B. Stinson, Prophylactic Ganciclovir Treatment Reduces Fungal As Well As Cytomegalovirus Infections After Heart Transplantation1,2 Transplantation. ,vol. 60, pp. 1473- 1477 ,(1995) , 10.1097/00007890-199560120-00018
E Speir, R Modali, E. Huang, M. Leon, F Shawl, T Finkel, S. Epstein, Potential Role of Human Cytomegalovirus and p53 Interaction in Coronary Restenosis Science. ,vol. 265, pp. 391- 394 ,(1994) , 10.1126/SCIENCE.8023160
William W. Parmley, Calcium channel blockers and atherogenesis The American Journal of Medicine. ,vol. 82, pp. 3- 8 ,(1987) , 10.1016/0002-9343(87)90204-X
Jennifer L. Craigen, Jane E. Grundy, Cytomegalovirus induced up-regulation of LFA-3 (CD58) and ICAM-1 (CD54) is a direct viral effect that is not prevented by ganciclovir or foscarnet treatment. Transplantation. ,vol. 62, pp. 1102- 1108 ,(1996) , 10.1097/00007890-199610270-00014